Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Aida Telegrafi is active.

Publication


Featured researches published by Aida Telegrafi.


Journal of Medical Genetics | 2015

Mutations in SLC1A4 , encoding the brain serine transporter, are associated with developmental delay, microcephaly and hypomyelination

Nadirah Damseh; Alexandre Simonin; Chaim Jalas; Joseph A. Picoraro; Avraham Shaag; Megan T Cho; Barak Yaacov; Julie Neidich; Motee Al-Ashhab; Jane Juusola; Sherri J. Bale; Aida Telegrafi; Kyle Retterer; John G. Pappas; Ellen Moran; Joshua Cappell; Kwame Anyane Yeboa; Bassam Abu-Libdeh; Matthias A. Hediger; Wendy K. Chung; Orly Elpeleg; Simon Edvardson

Background L-serine plays an essential role in neuronal development and function. Although a non-essential amino acid, L-serine must be synthesised within the brain because of its poor permeability by the blood–brain barrier. Within the brain, its synthesis is confined to astrocytes, and its shuttle to neuronal cells is performed by a dedicated neutral amino acid transporter, ASCT1. Methods and results Using exome analysis we identified the recessive mutations, p.E256K, p.L315fs, and p.R457W, in SLC1A4, the gene encoding ASCT1, in patients with developmental delay, microcephaly and hypomyelination; seizure disorder was variably present. When expressed in a heterologous system, the mutations did not affect the protein level at the plasma membrane but abolished or markedly reduced L-serine transport for p.R457W and p.E256K mutations, respectively. Interestingly, p.E256K mutation displayed a lower L-serine and alanine affinity but the same substrate selectivity as wild-type ASCT1. Conclusions The clinical phenotype of ASCT1 deficiency is reminiscent of defects in L-serine biosynthesis. The data underscore that ASCT1 is essential in brain serine transport. The SLC1A4 p.E256K mutation has a carrier frequency of 0.7% in the Ashkenazi-Jewish population and should be added to the carrier screening panel in this community.


American Journal of Medical Genetics Part A | 2016

Whole exome sequencing reveals de novo pathogenic variants in KAT6A as a cause of a neurodevelopmental disorder

Francisca Millan; Megan T. Cho; Kyle Retterer; Kristin G. Monaghan; Renkui Bai; Patrik Vitazka; David B. Everman; Brooke T. Smith; Brad Angle; Victoria Roberts; La Donna Immken; Honey Nagakura; Marc DiFazio; Elliott H. Sherr; Eden Haverfield; Bethany Friedman; Aida Telegrafi; Jane Juusola; Wendy K. Chung; Sherri J. Bale

Neurodevelopmental disorders (NDD) are common, with 1–3% of general population being affected, but the etiology is unknown in most individuals. Clinical whole‐exome sequencing (WES) has proven to be a powerful tool for the identification of pathogenic variants leading to Mendelian disorders, among which NDD represent a significant percentage. Performing WES with a trio‐approach has proven to be extremely effective in identifying de novo pathogenic variants as a common cause of NDD. Here we report six unrelated individuals with a common phenotype consisting of NDD with severe speech delay, hypotonia, and facial dysmorphism. These patients underwent WES with a trio approach and de novo heterozygous predicted pathogenic novel variants in the KAT6A gene were identified. The KAT6A gene encodes a histone acetyltransfrease protein and it has long been known for its structural involvement in acute myeloid leukemia; however, it has not previously been associated with any congenital disorder. In animal models the KAT6A ortholog is involved in transcriptional regulation during development. Given the similar findings in animal models and our patients phenotypes, we hypothesize that KAT6A could play a role in development of the brain, face, and heart in humans.


Cold Spring Harb Mol Case Stud | 2016

De novo pathogenic variants in CHAMP1 are associated with global developmental delay, intellectual disability, and dysmorphic facial features

Akemi J. Tanaka; Megan T. Cho; Kyle Retterer; Julie R. Jones; Catherine Nowak; Jessica Douglas; Yong-hui Jiang; Allyn McConkie-Rosell; G. Bradley Schaefer; Julie Kaylor; Omar A. Rahman; Aida Telegrafi; Bethany Friedman; Ganka Douglas; Kristin G. Monaghan; Wendy K. Chung

We identified five unrelated individuals with significant global developmental delay and intellectual disability (ID), dysmorphic facial features and frequent microcephaly, and de novo predicted loss-of-function variants in chromosome alignment maintaining phosphoprotein 1 (CHAMP1). Our findings are consistent with recently reported de novo mutations in CHAMP1 in five other individuals with similar features. CHAMP1 is a zinc finger protein involved in kinetochore–microtubule attachment and is required for regulating the proper alignment of chromosomes during metaphase in mitosis. Mutations in CHAMP1 may affect cell division and hence brain development and function, resulting in developmental delay and ID.


American Journal of Medical Genetics Part A | 2016

The role of objective facial analysis using FDNA in making diagnoses following whole exome analysis. Report of two patients with mutations in the BAF complex genes

Karen W. Gripp; Laura Baker; Aida Telegrafi; Kristin G. Monaghan

The genetic basis of numerous intellectual disability (ID) syndromes has recently been identified by applying exome analysis on a research or clinical basis. There is significant clinical overlap of biologically related syndromes, as exemplified by Nicolaides–Baraitser (NCBRS) and Coffin–Siris (CSS) syndrome. Both result from mutations affecting the BAF (mSWI/SNF) complex and belong to the growing category of BAFopathies. In addition to the notable clinical overlap between these BAFopathies, heterogeneity exists for patients clinically diagnosed with one of these conditions. We report two teenagers with ID whose molecular diagnosis of a SMARC2A or ARID1B mutation, respectively, was established through clinical exome analysis. Interestingly, using only the information provided in a single clinically obtained facial photograph from each patient, the facial dysmorphology analysis detected similarities to facial patterns associated with NCBRS as the first suggestion for both individuals, followed by CSS as the second highest ranked in the individual with the ARID1B mutation. Had this information been available to the laboratory performing the exome analysis, it could have been utilized during the variant analysis and reporting process, in conjunction with the written summary provided with each test requisition. While the available massive parallel sequencing technology, variant calling and variant interpretation are constantly evolving, clinical information remains critical for this diagnostic process. When trio analysis is not feasible, additional diagnostic tools may become particularly valuable. Facial dysmorphology analysis data may supplement the clinical phenotype summary and provide data independent of the clinicians personal experience and bias.


American Journal of Human Genetics | 2016

Variants in HNRNPH2 on the X Chromosome Are Associated with a Neurodevelopmental Disorder in Females

Jennifer M. Bain; Megan T. Cho; Aida Telegrafi; Ashley Wilson; Susan Sklower Brooks; Christina Botti; Gordon C. Gowans; Leigh Anne Autullo; Vidya Krishnamurthy; Marcia C. Willing; Tomi L. Toler; Bruria Ben-Zev; Orly Elpeleg; Yufeng Shen; Kyle Retterer; Kristin G. Monaghan; Wendy K. Chung

Via whole-exome sequencing, we identified six females from independent families with a common neurodevelopmental phenotype including developmental delay, intellectual disability, autism, hypotonia, and seizures, all with de novo predicted deleterious variants in the nuclear localization signal of Heterogeneous Nuclear Ribonucleoprotein H2, encoded by HNRNPH2, a gene located on the X chromosome. Many of the females also have seizures, psychiatric co-morbidities, and orthopedic, gastrointestinal, and growth problems as well as common dysmorphic facial features. HNRNPs are a large group of ubiquitous proteins that associate with pre-mRNAs in eukaryotic cells to produce a multitude of alternatively spliced mRNA products during development and play an important role in controlling gene expression. The failure to identify affected males, the severity of the neurodevelopmental phenotype in females, and the essential role of this gene suggests that male conceptuses with these variants may not be viable.


PLOS Genetics | 2017

Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies

Rocio Acuna-Hidalgo; Pelagia Deriziotis; Marloes Steehouwer; Christian Gilissen; Sarah A. Graham; Sipko van Dam; Julie Hoover-Fong; Aida Telegrafi; A Destree; Robert Smigiel; Lindsday A. Lambie; Hülya Kayserili; Umut Altunoglu; Elisabetta Lapi; Maria Luisa Giovannucci Uzielli; Mariana Aracena; Banu Nur; Ercan Mihci; Lilia Maria de Azevedo Moreira; Viviane Borges Ferreira; Dafne D. G. Horovitz; Kátia M. Rocha; Aleksandra Jezela-Stanek; Alice S. Brooks; Heiko Reutter; Julie S. Cohen; Ali Fatemi; Martin Smitka; Theresa A. Grebe; Nataliya Di Donato

Schinzel-Giedion syndrome (SGS) is a rare developmental disorder characterized by multiple malformations, severe neurological alterations and increased risk of malignancy. SGS is caused by de novo germline mutations clustering to a 12bp hotspot in exon 4 of SETBP1. Mutations in this hotspot disrupt a degron, a signal for the regulation of protein degradation, and lead to the accumulation of SETBP1 protein. Overlapping SETBP1 hotspot mutations have been observed recurrently as somatic events in leukemia. We collected clinical information of 47 SGS patients (including 26 novel cases) with germline SETBP1 mutations and of four individuals with a milder phenotype caused by de novo germline mutations adjacent to the SETBP1 hotspot. Different mutations within and around the SETBP1 hotspot have varying effects on SETBP1 stability and protein levels in vitro and in in silico modeling. Substitutions in SETBP1 residue I871 result in a weak increase in protein levels and mutations affecting this residue are significantly more frequent in SGS than in leukemia. On the other hand, substitutions in residue D868 lead to the largest increase in protein levels. Individuals with germline mutations affecting D868 have enhanced cell proliferation in vitro and higher incidence of cancer compared to patients with other germline SETBP1 mutations. Our findings substantiate that, despite their overlap, somatic SETBP1 mutations driving malignancy are more disruptive to the degron than germline SETBP1 mutations causing SGS. Additionally, this suggests that the functional threshold for the development of cancer driven by the disruption of the SETBP1 degron is higher than for the alteration in prenatal development in SGS. Drawing on previous studies of somatic SETBP1 mutations in leukemia, our results reveal a genotype-phenotype correlation in germline SETBP1 mutations spanning a molecular, cellular and clinical phenotype.


Annals of Neurology | 2018

Recessive mutations in >VPS13D cause childhood onset movement disorders

Julie Gauthier; Inge Meijer; Davor Lessel; Niccolo E. Mencacci; Dimitri Krainc; Maja Hempel; Konstantinos Tsiakas; Holger Prokisch; Elsa Rossignol; Margaret H. Helm; Lance H. Rodan; Jason Karamchandani; Miryam Carecchio; Steven Lubbe; Aida Telegrafi; Lindsay B. Henderson; Kerry Lorenzo; Wallace Se; Ian A. Glass; Fadi F. Hamdan; Jacques L. Michaud; Guy A. Rouleau; Philippe M. Campeau

VPS13 protein family members VPS13A through VPS13C have been associated with various recessive movement disorders. We describe the first disease association of rare recessive VPS13D variants including frameshift, missense, and partial duplication mutations with a novel complex, hyperkinetic neurological disorder. The clinical features include developmental delay, a childhood onset movement disorder (chorea, dystonia, or tremor), and progressive spastic ataxia or paraparesis. Characteristic brain magnetic resonance imaging shows basal ganglia or diffuse white matter T2 hyperintensities as seen in Leigh syndrome and choreoacanthocytosis. Muscle biopsy in 1 case showed mitochondrial aggregates and lipidosis, suggesting mitochondrial dysfunction. These findings underline the importance of the VPS13 complex in neurological diseases and a possible role in mitochondrial function. Ann Neurol 2018;83:1089–1095


American Journal of Medical Genetics Part A | 2017

Identification of STAC3 variants in non-Native American families with overlapping features of Carey–Fineman–Ziter syndrome and Moebius syndrome

Aida Telegrafi; Bryn D. Webb; Sarah Robbins; Carlos E. Speck‐Martins; David Fitzpatrick; Leah Fleming; Richard Redett; Andreas Dufke; Gunnar Houge; Jeske van Harssel; Alain Verloes; Angela Robles; Irini Manoli; Elizabeth C. Engle; Ethylin Wang Jabs; David Valle; John C. Carey; Julie Hoover-Fong; Nara Sobreira

Horstick et al. (2013) previously reported a homozygous p.Trp284Ser variant in STAC3 as the cause of Native American myopathy (NAM) in 5 Lumbee Native American families with congenital hypotonia and weakness, cleft palate, short stature, ptosis, kyphoscoliosis, talipes deformities, and susceptibility to malignant hyperthermia (MH). Here we present two non‐Native American families, who were found to have STAC3 pathogenic variants. The first proband and her affected older sister are from a consanguineous Qatari family with a suspected clinical diagnosis of Carey–Fineman–Ziter syndrome (CFZS) based on features of hypotonia, myopathic facies with generalized weakness, ptosis, normal extraocular movements, cleft palate, growth delay, and kyphoscoliosis. We identified the homozygous c.851G>C;p.Trp284Ser variant in STAC3 in both sisters. The second proband and his affected sister are from a non‐consanguineous, Puerto Rican family who was evaluated for a possible diagnosis of Moebius syndrome (MBS). His features included facial and generalized weakness, minimal limitation of horizontal gaze, cleft palate, and hypotonia, and he has a history of MH. The siblings were identified to be compound heterozygous for STAC3 variants c.851G>C;p.Trp284Ser and c.763_766delCTCT;p.Leu255IlefsX58. Given the phenotypic overlap of individuals with CFZS, MBS, and NAM, we screened STAC3 in 12 individuals diagnosed with CFZS and in 50 individuals diagnosed with MBS or a congenital facial weakness disorder. We did not identify any rare coding variants in STAC3. NAM should be considered in patients presenting with facial and generalized weakness, normal or mildly abnormal extraocular movement, hypotonia, cleft palate, and scoliosis, particularly if there is a history of MH.


Obstetrics & Gynecology | 2012

Perinatal detection of familial adenomatous polyposis.

Meredith L. Birsner; Julie Hoover-Fong; Aida Telegrafi; Nancy Hueppchen

BACKGROUND: Hepatoblastoma is an uncommon fetal neoplasm that may represent an isolated malignancy or a component of a familial cancer or syndromic diagnosis. CASE: A large fetal liver mass was detected on routine ultrasound examination of a 23-year-old woman with thyroid nodules and hypertension. Inferior vena cava compression prompted delivery; postnatal biopsy revealed hepatoblastoma. Maternal thyroid biopsy revealed papillary carcinoma. Neonatal and maternal cytomolecular analysis revealed APC gene disruption at 5q22.2. Pedigree analysis exposed multigenerational colon cancer and thyroid cancer, which in conjunction with genetic testing is consistent with familial adenomatous polyposis. CONCLUSION: This is a novel means of familial adenomatous polyposis diagnosis. Obstetricians and perinatologists should be alert for familial cancer or syndromic diagnoses presenting as fetal neoplasms.


American Journal of Medical Genetics Part A | 2018

De novo variants in Myelin regulatory factor (MYRF) as candidates of a new syndrome of cardiac and urogenital anomalies

Hailey Pinz; Louise C. Pyle; Dong Li; Kosuke Izumi; Cara Skraban; Jennifer Tarpinian; Stephen R. Braddock; Aida Telegrafi; Kristin G. Monaghan; Elaine H. Zackai; Elizabeth J. Bhoj

Myelin Regulatory Factor (MYRF) is a transcription factor that has previously been associated with the control of the expression of myelin‐related genes. However, it is highly expressed in human tissues and mouse embryonic tissues outside the nervous system such as the stomach, lung, and small intestine. It has not previously been reported as a cause of any Mendelian disease. We report here two males with Scimitar syndrome [MIM 106700], and other features including penoscrotal hypospadias, cryptorchidism, pulmonary hypoplasia, tracheal anomalies, congenital diaphragmatic hernia, cleft spleen, thymic involution, and thyroid fibrosis. Gross neurologic functioning appears to be within normal limits. In both individuals a de novo variant in MYRF was identified using exome sequencing. Neither variant is found in gnomAD. Heterozygous variants in MYRF should be considered in patients with variants of Scimitar syndrome and urogenital anomalies.

Collaboration


Dive into the Aida Telegrafi's collaboration.

Researchain Logo
Decentralizing Knowledge